In a randomized controlled trial (RCT) study, the result showed that fucoidan may decrease the blood alanine transaminase (ALT) level and maintain liver function in nonalcoholic fatty liver disease [15]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.